Literature DB >> 20456973

Estrogen and ERalpha: culprits in cervical cancer?

Sang-Hyuk Chung1, Silvia Franceschi, Paul F Lambert.   

Abstract

Estrogen and its receptors are implicated in the promotion and prevention of various cancers. Although the uterine cervix is highly responsive to estrogen, the role of estrogen in cervical cancer, which is strongly associated with human papillomavirus (HPV) infections, is poorly understood. Recent studies in HPV transgenic mouse models provide evidence that estrogen and its nuclear receptor promote cervical cancer in combination with HPV oncogenes. Although epidemiological studies further support this hypothesis, there is little experimental data assessing the hormonal responsiveness of human cervical cancers. If these cancers are dependent on estrogen, then drugs targeting estrogen and its receptors could be effective in treating and/or preventing cervical cancer, the second leading cause of death by cancer among women worldwide. Copyright (c) 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20456973      PMCID： PMC2914219          DOI： 10.1016/j.tem.2010.03.005

Source DB:  PubMed          Journal:  Trends Endocrinol Metab        ISSN： 1043-2760            Impact factor:   12.015


  61 in total

1.  Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.

Authors:  Victor G Vogel; Joseph P Costantino; D Lawrence Wickerham; Walter M Cronin; Reena S Cecchini; James N Atkins; Therese B Bevers; Louis Fehrenbacher; Eduardo R Pajon; James L Wade; André Robidoux; Richard G Margolese; Joan James; Scott M Lippman; Carolyn D Runowicz; Patricia A Ganz; Steven E Reis; Worta McCaskill-Stevens; Leslie G Ford; V Craig Jordan; Norman Wolmark
Journal:  JAMA       Date:  2006-06-05       Impact factor: 56.272

Review 2.  Molecular targets and anticancer potential of indole-3-carbinol and its derivatives.

Authors:  Bharat B Aggarwal; Haruyo Ichikawa
Journal:  Cell Cycle       Date:  2005-09-06       Impact factor: 4.534

3.  Human papillomavirus E7 oncoprotein dysregulates steroid receptor coactivator 1 localization and function.

Authors:  Amy Baldwin; Kyung-Won Huh; Karl Münger
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

4.  In vitro response of cervical cancer cell lines CaSki, HeLa, and ME-180 to the antiestrogen tamoxifen.

Authors:  S Grenman; A Shapira; T E Carey
Journal:  Gynecol Oncol       Date:  1988-06       Impact factor: 5.482

Review 5.  Role of steroid hormones in potentiating transformation of cervical cells by human papillomaviruses.

Authors:  M M Pater; R Mittal; A Pater
Journal:  Trends Microbiol       Date:  1994-07       Impact factor: 17.079

6.  Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study.

Authors:  Margaret R E McCredie; Katrina J Sharples; Charlotte Paul; Judith Baranyai; Gabriele Medley; Ronald W Jones; David C G Skegg
Journal:  Lancet Oncol       Date:  2008-04-11       Impact factor: 41.316

Review 7.  Human papillomavirus, cervical carcinogenesis and chemoprevention with Indole derivates - a review of pathomechanisms.

Authors:  Gudrun C Rieck; Alison N Fiander
Journal:  Mol Nutr Food Res       Date:  2008-01       Impact factor: 5.914

8.  The upstream regulatory region of the human papilloma virus-16 contains an E2 protein-independent enhancer which is specific for cervical carcinoma cells and regulated by glucocorticoid hormones.

Authors:  B Gloss; H U Bernard; K Seedorf; G Klock
Journal:  EMBO J       Date:  1987-12-01       Impact factor: 11.598

9.  Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen.

Authors:  Mitch Dowsett; Jack Cuzick; Jim Ingle; Alan Coates; John Forbes; Judith Bliss; Marc Buyse; Michael Baum; Aman Buzdar; Marco Colleoni; Charles Coombes; Claire Snowdon; Michael Gnant; Raimund Jakesz; Manfred Kaufmann; Francesco Boccardo; Jon Godwin; Christina Davies; Richard Peto
Journal:  J Clin Oncol       Date:  2009-11-30       Impact factor: 44.544

10.  A case-control study of endogenous hormones and cervical cancer.

Authors:  T S Shields; R T Falk; R Herrero; M Schiffman; N S Weiss; C Bratti; A C Rodriguez; M E Sherman; R D Burk; A Hildesheim
Journal:  Br J Cancer       Date:  2004-01-12       Impact factor: 7.640
View more
  69 in total

Review 1.  Regulation of 17β-hydroxysteroid dehydrogenases in cancer: regulating steroid receptor at pre-receptor stage.

Authors:  Mirja Rotinen; Joaquín Villar; Ignacio Encío
Journal:  J Physiol Biochem       Date:  2012-02-29       Impact factor: 4.158

2.  Association of Estrogen Receptor Alpha Expression With Survival in Oropharyngeal Cancer Following Chemoradiation Therapy.

Authors:  Maria B Koenigs; Armida Lefranc-Torres; Juliana Bonilla-Velez; Krupal B Patel; D Neil Hayes; Krzysztof Glomski; Paul M Busse; Annie W Chan; John R Clark; Daniel G Deschler; Kevin S Emerick; Rebecca J Hammon; Lori J Wirth; Derrick T Lin; Edmund A Mroz; William C Faquin; James W Rocco
Journal:  J Natl Cancer Inst       Date:  2019-09-01       Impact factor: 13.506

3.  Progesterone signaling inhibits cervical carcinogenesis in mice.

Authors:  Young A Yoo; Jieun Son; Fabiola F Mehta; Francesco J DeMayo; John P Lydon; Sang-Hyuk Chung
Journal:  Am J Pathol       Date:  2013-09-05       Impact factor: 4.307

4.  Suppression of indoleamine-2,3-dioxygenase 1 expression by promoter hypermethylation in ER-positive breast cancer.

Authors:  Dyah L Dewi; Soumya R Mohapatra; Saioa Blanco Cabañes; Isabell Adam; Luis F Somarribas Patterson; Bianca Berdel; Masroor Kahloon; Loreen Thürmann; Stefanie Loth; Katharina Heilmann; Dieter Weichenhan; Oliver Mücke; Ines Heiland; Pauline Wimberger; Jan Dominik Kuhlmann; Karl-Heinz Kellner; Sarah Schott; Christoph Plass; Michael Platten; Clarissa Gerhäuser; Saskia Trump; Christiane A Opitz
Journal:  Oncoimmunology       Date:  2017-01-03       Impact factor: 8.110

5.  Recurrence of cervical cancer in mice after selective estrogen receptor modulator therapy.

Authors:  Megan E Spurgeon; Sang-Hyuk Chung; Paul F Lambert
Journal:  Am J Pathol       Date:  2014-02       Impact factor: 4.307

6.  Time since first sexual intercourse and the risk of cervical cancer.

Authors:  Martyn Plummer; Julian Peto; Silvia Franceschi
Journal:  Int J Cancer       Date:  2011-08-12       Impact factor: 7.396

7.  Calcium-activated potassium channels as potential early markers of human cervical cancer.

Authors:  Ana Ramírez; Eunice Vera; Armando Gamboa-Domínguez; Paul Lambert; Patricio Gariglio; Javier Camacho
Journal:  Oncol Lett       Date:  2018-03-07       Impact factor: 2.967

8.  Requirement for stromal estrogen receptor alpha in cervical neoplasia.

Authors:  Sang-Hyuk Chung; Myeong Kyun Shin; Kenneth S Korach; Paul F Lambert
Journal:  Horm Cancer       Date:  2012-10-13       Impact factor: 3.869

9.  In vitro fertilization and risk of breast and gynecologic cancers: a retrospective cohort study within the Israeli Maccabi Healthcare Services.

Authors:  Louise A Brinton; Britton Trabert; Varda Shalev; Eitan Lunenfeld; Tal Sella; Gabriel Chodick
Journal:  Fertil Steril       Date:  2013-01-30       Impact factor: 7.329

Review 10.  Human papillomavirus infections: warts or cancer?

Authors:  Louise T Chow; Thomas R Broker
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-07-01       Impact factor: 10.005
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.